<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04454216</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00104116</org_study_id>
    <nct_id>NCT04454216</nct_id>
  </id_info>
  <brief_title>GSD IX Natural History Study</brief_title>
  <official_title>Clinical and Molecular Evaluations in Glycogen Storage Disease Type IX</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      GSD IX patients will be consented to this natural history chart review study. Data will be
      collected from medical charts including, but not limited to: physical examinations, imaging
      studies, review of systems, age of diagnosis, quality of life surveys, growth delay
      assessment, metabolic control, dietary analysis, urine and blood labs, muscle strength, lab
      test results, biopsy specimens, gene sequencing, oligosaccharide and ketone analysis and
      biotinidase activity levels. Participant's medical charts will be continually reviewed for
      the duration of the study. If a liver, muscle or skin biopsy sample has been collected, a
      piece of the sample may be requested and stored for research purposes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">April 2030</completion_date>
  <primary_completion_date type="Anticipated">April 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum biotinidase activity</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of genotypes presented</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of phenotypes presented</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Glycogen Storage Disease</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Liver, muscle and skin tissue samples may be collected and stored for research purposes.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with diagnosed Glycogen Storage Disease type IX.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - enzymatically confirmed diagnosis of GSD IX of any variant defined as very low or absent
        phosphorylase kinase activity in blood RBCs, liver or muscle biopsy.

        Exclusion Criteria:

        - No enzymatically confirmed diagnosis of GSD IX
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Priya Kishnani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara Roy, MSCR</last_name>
    <phone>9196600758</phone>
    <email>sara.roy@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Paschall</last_name>
    <email>anna.paschall@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Roy, MSCR</last_name>
      <phone>919-660-0758</phone>
      <email>sara.roy@duke.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 29, 2020</study_first_submitted>
  <study_first_submitted_qc>June 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2020</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycogen Storage Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

